Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AAV9-based gene therapy construct
- Development stage
- Preclinical
- Lead developer
- Medical University of South Carolina
- Modality
- Gene Therapies
01
Overview
AAV9-based gene therapy construct is an investigational adeno-associated virus serotype 9 (AAV9) gene therapy candidate being developed by the Medical University of South Carolina for the treatment of cervical dysplasia and HPV-positive cervical cancer. The therapy utilizes a series of rationally designed synthetic AAV transgene promoters that are selectively activated in HPV-positive cervical cancer cells by leveraging dysregulated E2F transcription factor activity. This tumor-specific promoter system is designed to deliver therapeutic payloads specifically to cervical cancer cells while minimizing expression in normal epithelial tissues.
02
Targets
E2F (E2F transcription factor family)
Beyond the preview
Go deeper on AAV9-based gene therapy construct.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AAV9-based gene therapy construct.